Table 2 Patient background of the HDA/MDA and LDA/REM groups
Characteristics | HDA/MDA (N = 105) | LDA/REM (N = 195) | P |
|---|---|---|---|
Age, years | 65.3 ± 14.2 | 65.5 ± 14.6 | 0.7303 |
Female, % | 78.1 | 81.5 | 0.4742 |
Disease duration, months | 108.5 ± 145.7 | 101.0 ± 103.0 | 0.1375 |
Stage (I/II/III/IV), % | 42.7/19.1/19.1/19.1 | 45.7/30.8/12.3/11.2 | 0.0337 |
TJC, 0–28 | 6.7 ± 5.1 | 0.9 ± 0.1 | < 0.0001 |
SJC, 0–28 | 4.4 ± 4.3 | 0.3 ± 0.6 | < 0.0001 |
CRP, mg/dL | 1.7 ± 2.7 | 0.3 ± 0.6 | < 0.0001 |
ESR, mm/h | 35.5 ± 31.9 | 18.5 ± 17.4 | < 0.0001 |
RF, IU/mL | 176.6 ± 276.5 | 92.5 ± 170.7 | 0.1713 |
RF positive, % | 63.5 | 60.0 | 0.5585 |
CCP, U/mL | 322.1 ± 533.7 | 212.8 ± 310.9 | 0.6343 |
CCP positive, % | 66.7 | 66.5 | 0.9751 |
MMP-3, ng/mL | 225.7 ± 348.9 | 78.5 ± 80.4 | < 0.0001 |
SDAI | 22.9 ± 11.8 | 4.0 ± 3.2 | < 0.0001 |
MTX use, % | 53.3 | 69.2 | 0.0063 |
MTX, mg/w | 8.9 ± 3.2 | 8.6 ± 3.5 | 0.0389 |
PSL use, % | 13.3 | 12.3 | 0.7989 |
PSL, mg/d | 5.8 ± 4.4 | 4.0 ± 2.6 | 0.7517 |
b(ts)DMARD use, % | 29.5 | 42.1 | 0.0327 |
HAQ-DI | 1.5 ± 0.8 | 0.5 ± 0.7 | < 0.0001 |
EQ-5D-5L | 0.6 ± 0.2 | 0.8 ± 0.1 | < 0.0001 |
MS, min | 332.5 ± 568.2 | 46.2 ± 210.9 | < 0.0001 |
Pain VAS score, 0–100, mm | 59.6 ± 24.0 | 16.0 ± 18.2 | < 0.0001 |
Fatigue VAS score, 0–100, mm | 58.1 ± 25.3 | 18.7 ± 22.1 | < 0.0001 |
EGA, 0–100, mm | 35.2 ± 20.2 | 6.4 ± 7.2 | < 0.0001 |
GS sum | 5.5 ± 7.1 | 1.8 ± 2.9 | < 0.0001 |
GS score ≥ 1, % | 82.9 | 56.4 | < 0.0001 |
GS score ≥ 2, % | 59.0 | 23.6 | < 0.0001 |
GS score ≥ 3, % | 25.7 | 8.2 | < 0.0001 |
PD sum | 2.6 ± 4.3 | 0.6 ± 1.7 | < 0.0001 |
PD score ≥ 1, % | 55.2 | 22.6 | < 0.0001 |
PD score ≥ 2, % | 40.0 | 13.3 | < 0.0001 |
PD score ≥ 3, % | 2.9 | 2.6 | 0.8806 |